The psychological burden during COVID-19 pandemic in a cohort of patients affected by moderate-to-severe atopic dermatitis treated with dupilumab
Laura Quattrini(Agostino Gemelli University Polyclinic), Ketty Peris(Agostino Gemelli University Polyclinic), Lucia Di Nardo(Università Cattolica del Sacro Cuore), Luigi Cornacchia(Università Cattolica del Sacro Cuore), Silvia Catapano(Agostino Gemelli University Polyclinic), Dalma Malvaso(Agostino Gemelli University Polyclinic), Andrea Chiricozzi(Università Cattolica del Sacro Cuore), Dario Francesco D'Urso(Università Cattolica del Sacro Cuore), Niccolò Gori(Università Cattolica del Sacro Cuore)
Cited by 1
Related Papers
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
|Clinical Reviews in Allergy & Immunology|2018|738
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
|European Journal of Cancer|2016|579
Scanning the Immunopathogenesis of Psoriasis
|International Journal of Molecular Sciences|2018|317
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline
|European Journal of Cancer|2009|316